AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved Lynparza (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic….